comparemela.com

Latest Breaking News On - Alexander zwyer - Page 1 : comparemela.com

NLS Pharmaceutics : Ordinary Shareholders Meeting Results - Form 6-K -December 22, 2023 at 04:05 pm EST

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K Report of Foreign Private Issuer .

United statesAlexander zwyerSecurities exchangePharmaceutics ltdExchange commissionForeign private issuerSecurities exchange actRegistration statements

NLS Pharmaceutics : UNAUDITED INTERIM CONDENSED FINANCIAL STATEMENTS - Form 6-K -December 06, 2023 at 04:49 pm EST

UNAUDITED INTERIM CONDENSED FINANCIAL STATEMENTS Page .

United statesSilvia panigoneSubhasis royCarlos camozziMarianne lambertsonFelix grisardEric konofalGeorge apostolMaria nayvaltRonald hafnerUs eric konofalAlexander zwyerThomas curatoloAstrid sommerCompany board of directorsCompany annual report on form

NLS Pharmaceutics Acquires Rights to Orexin Agonist Platform

NLS Pharmaceutics entered into an exclusive option agreement with Aexon Labs to develop its dual orexin receptor agonists platform.

Alexander zwyerEric konofalAexon labs incPharmaceutics ltdAexon labKleine levin syndromeAexon labs

NLS Pharmaceutics Announces Exclusive Option Agreement to Develop and Commercialize Next Generation Dual Orexin Agonist Platform of Aexon Labs, Inc

NLS Pharmaceutics Announces Exclusive Option Agreement to Develop and Commercialize Next Generation Dual Orexin Agonist Platform of Aexon Labs, Inc
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

Eric konofalMarianne lambertsonAlexander zwyerDrug administrationAexon labs incPharmaceutics ltdAexon labExchange commissionAexon lab dual orexin receptor agonistsAexon labsChief scientific officerChief executive officerKleine levin syndromeAmyotrophic lateral sclerosis

NLS Pharmaceutics Announces Exclusive Option Agreement to Develop and

NLS Pharmaceutics Announces Exclusive Option Agreement to Develop and .

Alexander zwyerEric konofalPharmaceutics ltdAexon lab dual orexin receptor agonistsNews networkAexon labAexon labs incDrug administrationAexon labsChief scientific officerChief executive officerKleine levin syndromeAmyotrophic lateral sclerosisHarbor statement

vimarsana © 2020. All Rights Reserved.